Ishii Satoru, Iikura Motoyasu, Sugiura Yuriko, Matsuki Rei, Izumi Shinyu, Hojo Masayuki, Sugiyama Haruhito
Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-Ku, Tokyo, 162-8655, Japan.
Respir Med Case Rep. 2022 Jun 13;38:101685. doi: 10.1016/j.rmcr.2022.101685. eCollection 2022.
Bronchial thermoplasty (BT) is a type of bronchoscopic treatment specifically used for patients with severe asthma. Most severe asthmatics receive systemic steroids and are at risk of being immunocompromised. This raises the clinical question of whether or not BT can be effectively and safely performed in such patients. Herein, we report a case highlighting the effectiveness and safety of BT in a patient with severe persistent bronchial asthma and infection We performed BT on a 46-year-old woman undergoing treatment for severe persistent asthma with inhaled steroids and 20 mg prednisolone orally. Although she was deemed to be infection-free before the procedure, culture of endobronchial secretions obtained during the first BT procedure grew . After the first BT, she was given clarithromycin 400 mg orally daily. The amount of sputum decreased with each BT session, and sputum culture for turned negative by the third BT session. Respiratory function tests showed 23.7% improvement in % post-bronchodilator forced expiratory volume in 1.0 s (%FEV) and the asthma quality of life questionnaire (AQLQ) score increased by 2.41 points after the third BT. Bronchial wall thickness decreased and infiltrative shadows on CT disappeared after the three BT sessions, along with decrease in the amount of purulent sputum. Improvement in her asthma symptoms, after three BT sessions allowed decrease in the prednisolone dose. We report the effectiveness of BT and infection control in a severe asthmatic with infection.
支气管热成形术(BT)是一种专门用于重度哮喘患者的支气管镜治疗方法。大多数重度哮喘患者接受全身类固醇治疗,有免疫功能低下的风险。这就引发了一个临床问题,即BT能否在此类患者中有效且安全地进行。在此,我们报告一例病例,突出了BT在一名患有重度持续性支气管哮喘并伴有感染的患者中的有效性和安全性。我们对一名46岁的女性进行了BT,该患者正在接受吸入类固醇和口服20毫克泼尼松龙治疗重度持续性哮喘。尽管在手术前她被认为没有感染,但在第一次BT手术期间获取的支气管内分泌物培养结果呈阳性。第一次BT后,她每天口服400毫克克拉霉素。每次BT治疗后痰液量都减少,到第三次BT治疗时痰液培养结果转阴。呼吸功能测试显示,支气管扩张后1.0秒用力呼气容积(%FEV)提高了23.7%,第三次BT后哮喘生活质量问卷(AQLQ)评分提高了2.41分。三次BT治疗后,支气管壁厚度减小,CT上的浸润阴影消失,脓性痰液量也减少。经过三次BT治疗后,她的哮喘症状得到改善,泼尼松龙剂量得以减少。我们报告了BT在一名患有感染的重度哮喘患者中的有效性及感染控制情况。